AnaptysBio Prepares for a Potential Gear Shift [The Motley Fool]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: The Motley Fool
AnaptysBio Prepares for a Potential Gear Shift During the second quarter, the company upgraded the safety net under its lead candidate. There wasn't much financial activity to report during the second quarter of 2019, but it was still a rough one for AnaptysBio ( NASDAQ:ANAB ) and its lead candidate, etokimab. Positive midstage clinical trial results that the company announced in early June didn't ignite any fireworks for the stock, but early results from a similar new drug candidate that Regeneron ( NASDAQ:REGN ) is developing took a heavy toll . Data source: AnaptysBio. In June, AnaptysBio released results from a 25-patient study with etokimab and patients with severe asthma. Two days after beginning the trial, patients treated with a single infusion of etokimab increased their forced expiration volume scores by 12%, compared with a 4% gain over baseline reported from the placebo group. At Day 64, the placebo group was still at 4% while the etokimab group's improvement relative to
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- Anaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Anaptys Announces Participation in November and December Investor ConferencesGlobeNewswire
- AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 11/5/24 - Beat
ANAB
Sec Filings
- 11/5/24 - Form S-3
- 11/5/24 - Form 10-Q
- 11/5/24 - Form 8-K
- ANAB's page on the SEC website